Complete Guide to Peptides for Fat Loss, Muscle Building & Longevity | Dr. Kyle Gillett MD
A 38-minute interview in which Dr. Kyle Gillett sorts peptides into classes, from growth hormone secretagogues to GLP-1s and SARMs, and gives his views on risks and use.
With Dr. Kyle Gillett (MD)
Key moments
Tap a moment to play the video from there.
- 2:26Growth hormone-releasing peptide basicsGillett explains the two GHRP families, ghrelin agonists and GHRH analogs, and why he sometimes pairs low doses of each.
- 7:18Target IGF-1 range and ageHe describes his rule of thumb for IGF-1 and why he thinks the acceptable level differs between children and older adults.
- 8:49Contraindications and glucose effectsHe lists active tumors as a contraindication and describes a reversible rise in blood glucose he links to some of these compounds.
- 10:56BPC-157 and vascular growth factorGillett describes BPC-157 as angiogenic, compares its role to platelet-rich plasma, and raises tumor growth as the main risk.
- 13:58BPC-157 dosing and resultsHe says typical regimens are two to three injections a week for two to six weeks and shares his own and his patients' experience.
- 15:20TB-500 and GHK copper peptideHe presents these as more targeted alternatives to raising growth hormone and notes they are used off label.
- 20:39Melanocortins and PT-141Gillett covers the melanocortin family, PT-141's approved use, side effects and his melanoma-related cautions.
- 27:33Amylin analogs with insulinHe explains amylin's role, why it is paired with insulin, and who he thinks might be a candidate.
- 30:55GLP-1 drugs and low dosingHe names several GLP-1 drugs and argues most people without diabetes do not need the strongest options.
- 33:02SARMs and ostarineHe discusses selective androgen receptor modulators, ostarine's clinical path, low SHBG and the hormonal suppression he says they cause.
What the video says
Thomas DeLauer interviews Dr. Kyle Gillett, who says he prefers to think of peptides by class rather than one at a time. The conversation moves through growth hormone-releasing peptides, BPC-157, TB-500 and GHK copper peptide, the melanocortins, amylin analogs, GLP-1 drugs and finally SARMs. A short sponsor segment for a grocery service sits near the start.
On growth hormone-releasing peptides, Gillett separates ghrelin-type agonists from GHRH analogs and says he favors low doses of both together to limit side effects. He names tesamorelin as his usual choice and says it recently gained FDA approval. He gives an IGF-1 range of about 100 to 250 as his rule of thumb and describes a reversible, diabetes-like rise in glucose that he links to some of these compounds. He lists active tumors as a key contraindication.
For BPC-157, TB-500 and GHK copper peptide, Gillett describes them as lower-risk, more targeted options than raising growth hormone broadly, but all are used off label. He says he has seen good results for tendon problems in himself and in patients, prefers short courses, and notes the same tumor-growth concern. He is skeptical of thymus peptides for immunity.
He then covers melanocortins such as PT-141, listing nausea, darker skin and a theoretical melanoma worry among the concerns. He describes amylin analogs as an add-on to insulin that can lower weight, and says GLP-1 drugs are often unnecessary at high doses, preferring one-fifth to one-tenth of the maximum. The closing section covers SARMs, where he discusses ostarine's clinical progress, low SHBG and some hormonal suppression. Everything here is his opinion and clinical experience.
On each compound
Tesamorelin5:42
Gillett names tesamorelin as his go-to GHRH analog. He says it has recently gained FDA approval for three indications, which is why he thinks older options are used less.
See how your DNA reads TesamorelinSermorelin6:15
According to Gillett, sermorelin has been around the longest and was among the first to go through clinical trial stages. He says it is used less now because of tesamorelin.
See how your DNA reads SermorelinBPC-15710:56
Gillett calls BPC-157 the only peptide he knows of that is angiogenic and compares its effect to platelet-rich plasma. He describes good anecdotal results for tendons, says it is used off label, and flags tumor growth as the main concern.
See how your DNA reads BPC-157TB-50015:20
Gillett describes TB-500 as a fragment of thymosin beta 4 that is often used alongside BPC-157. He recommends shorter courses and notes it has no approved indication.
See how your DNA reads TB-500GHK-Cu15:20
Gillett says GHK copper peptide is a more targeted option than raising growth hormone everywhere. He also mentions checking copper levels in people with bariatric surgery or unexplained low blood counts.
See how your DNA reads GHK-CuThymosin Alpha-117:35
Gillett says thymus-related peptides such as thymosin alpha 1 have been used for immunity, but he has not seen good results with them. He adds that the data and risk-benefit picture are weak.
See how your DNA reads Thymosin Alpha-1CJC-129518:07
Gillett says a clinical trial of CJC in Brazil was stopped after a death. He says some practitioners still prefer it but he does not.
See how your DNA reads CJC-1295Melanotan II20:39
Gillett lists MT1 and MT2 among the melanocortin agonists and describes side effects including nausea and darker skin. He says he treats a personal or family melanoma history, or high-risk skin type, as a contraindication.
See how your DNA reads Melanotan IIPT-14121:11
Gillett says PT-141 (bremelanotide, Vyleesi) is approved for hypoactive sexual desire disorder in women, though he says it acts in both sexes. He says its effects come on within minutes and it does not cause a loss of libido after stopping.
See how your DNA reads PT-141Semaglutide30:55
Gillett calls semaglutide the main GLP-1 drug and says about 98 percent of people without diabetes need nothing stronger. He says he often prescribes one-fifth to one-tenth of the maximum dose.
See how your DNA reads Semaglutide“an igf-1 between about 100 and 250 is the Goldilocks zone”
What this video doesn’t settle
- The video is one clinician's opinion and anecdotal experience with patients, with no controlled data presented for BPC-157, TB-500 or GHK copper peptide.
- Gillett's dosing figures and the IGF-1 range are his own rules of thumb, and the video does not show evidence for them.
- His claim that no melanoma cases have been reported with melanocortin agonists comes from conversations with company representatives, not published data shown on screen.
Questions this video answers
What does Dr. Kyle Gillett say about BPC-157 dosing?
Gillett says most regimens are subcutaneous, two to three times a week for two to six weeks. He says that if nothing is noticed in the first two to four weeks, it is unlikely to work, and he disagrees with the idea that it must be used continuously.
What are the main risks of growth hormone-releasing peptides according to Gillett?
He names tumor growth as the central concern and says active tumors are a contraindication. He also describes raised glucose, which he calls reversible, plus anxiety and sleepiness.
What IGF-1 level does Gillett consider reasonable?
His rule of thumb is an IGF-1 between about 100 and 250. He says too high raises tumor, glucose and insulin resistance concerns, while too low risks muscle loss and added fat.
Does Gillett think most people need high-dose GLP-1 drugs?
No. He says that for about 98 percent of people without diabetes, semaglutide is as strong as needed. He prefers low doses so people can build lifestyle habits.
What does Gillett say about SARMs?
He says they are not free of suppression, describing some pituitary and hypothalamic effects and a very low SHBG with certain compounds. He is hopeful about ostarine's clinical progress for hormone-responsive cancers.
Video by Thomas DeLauer on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
